Effects of thymoquinone on STZ-induced diabetic nephropathy: An immunohistochemical study

Ultrastructural Pathology

Volumn 38, Issue 1, 2014, Pages 26-33

  Omran, Ola M ^a,b  

^a QASSIM UNIVERSITY   (Saudi Arabia)

^b Assiut University   (Egypt)

Author keywords

Desmin; Diabetic nephropathy; FSP 1; MMP17; Streptozotocin; Thymoquinone; ZO 1

Indexed keywords

BENZOQUINONE DERIVATIVE; CALCIUM BINDING PROTEIN; FSP1 PROTEIN, RAT; MATRIX METALLOPROTEINASE 17; THYMOQUINONE;

ANIMAL; ARTICLE; DIABETIC NEPHROPATHY; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; METABOLISM; PATHOLOGY; RAT;

ANIMALS; BENZOQUINONES; CALCIUM-BINDING PROTEINS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; MATRIX METALLOPROTEINASE 17; RATS;

EID: 84893005448     PISSN: 01913123     EISSN: 15210758     Source Type: Journal    
DOI: 10.3109/01913123.2013.830166     Document Type: Article

References (37)

1. Sharma S, Anjaneyulu M, Kulkarni SK, Chopra K. Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology 2006;76: 69-75. (Pubitemid 43131538)
2. Li Y, Kang YS, Dai C, et al. Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol 2008;172: 299-308. (Pubitemid 351282018)
3. Yamaguchi Y, Iwano M, Suzuki D, et al. Epithelial- mesenchymal transition as a potential explanation for podocyte depletion in diabetic nephropathy. Am J Kidney Dis 2009;54: 653-64.
4. Tan RJ, Liu Y. Matrix metalloproteinases in kidney homeostasis and diseases. Am J Physiol Renal Physiol 2012;302: F1351-61.
5. Thrailkill KM, Clay Bunn R, Fowlkes JL. Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. Endocrine 2009;35: 1-10.
6. Srichai MB, Colleta H, Gewin L, et al. Membrane-type 4 matrix metalloproteinase (MT4-MMP) modulates water homeostasis in mice. PLoS One 2011;6: e17099.
7. Gross ML, Ritz E, Schoof A, et al. Comparison of renal morphology in the streptozotocin and the SHR/N-cp models of diabetes. Lab Invest 2004;84: 452-64. (Pubitemid 41656473)
8. Lee SE, Ma W, Rattigan EM, et al. Ultrastructural features of retinal capillary basement membrane thickening in diabetic swine. Ultrastruct Pathol 2010;34: 35-41.
9. Omran OM. Histopathological study of evening primrose oil effects on experimental diabetic neuropathy. Ultrastruct Pathol 2012;36: 222-7.
10. Kanter M. Protective effects of thymoquinone on streptozotocin- induced diabetic nephropathy. J Mol Histol 2009;40: 107-15.
11. Khan MA, Sattar MA, Abdullah NA, et al. Functional subtypes of renal alpha1-adrenoceptor in spontaneously hypertensive rats with streptozotocin- induced experimental diabetic nephropathy. Kidney Blood Press Res 2009;32: 349-59.
12. Gali-Muhtasib H, Diab-Assaf M, Boltze C, et al. Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53- dependent mechanism. Int J Oncol 2004;25: 857-66.
13. Haider S, Ahmed S, Tabassum S, et al. Streptozotocininduced insulin deficiency leads to development of behavioral deficits in rats. Acta Neurol Belg 2013;113: 35-41.
14. Kanter M, Coskun O, Uysal H. The antioxidative and antihistaminic effect of Nigella sativa and its major constituent, thymoquinone, on ethanol-induced gastric mucosal damage. Arch Toxicol 2006;80: 217-24.
15. Schena FP, Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 2005;16: S30-3. Review. (Pubitemid 41725079)
16. Rossing P. Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr Diab Rep 2006;6: 479-83. Review. (Pubitemid 44896409)
17. Carpenter L, Cordery D, Biden TJ. Inhibition of protein kinase C delta protects rat INS-1 cells against interleukin- 1beta and streptozotocin-induced apoptosis. Diabetes 2002;51: 317-24. (Pubitemid 34764786)
18. Bendayan M. Immunocytochemical detection of advanced glycated end products in rat renal tissue as a function of age and diabetes. Kidney Int 1998;54: 438-47. (Pubitemid 28357406)
19. Makino H, Miyamoto Y, Sawai K, et al. Altered gene expression related to glomerulogenesis and podocyte structure in early diabetic nephropathy of db/db mice and its restoration by pioglitazone. Diabetes 2006;55: 2747-56. (Pubitemid 44923673)
20. Zhou G, Li C, Cai L. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway. Am J Pathol 2004;165: 2033-43. (Pubitemid 39578381)
21. Alsaad KO, Herzenberg AM. Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update. J Clin Pathol 2007;60: 18-26. Review. (Pubitemid 46142667)
22. Benzing T. Signaling at the slit diaphragm. J Am Soc Nephrol 2004;15: 1382-91. Review. (Pubitemid 38679663)
23. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006;69: 2131-47. (Pubitemid 43882099)
24. Nishitani Y, Iwano M, Yamaguchi Y, et al. Fibroblastspecific protein 1 is a specific prognostic marker for renal survival in patients with IgAN. Kidney Int 2005;68: 1078-85. (Pubitemid 43246424)
25. Horster MF, Braun GS, Huber SM. Embryonic renal epithelia: induction, nephrogenesis, and cell differentiation. Physiol Rev 1999;79: 1157-91. Review. (Pubitemid 29473314)
26. Kuhlmann A, Haas CS, Gross ML, et al. 1,25- Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004;286: F526-33.
27. Zou J, Yaoita E, Watanabe Y, et al. Upregulation of nestin, vimentin, and desmin in rat podocytes in response to injury. Virchows Arch 2006;448: 485-92.
28. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005;54: 1626-34. (Pubitemid 40770751)
29. Sun SZ, Wang Y, Li Q, et al. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase- 2 and tissue inhibitor of metalloproteinase- 2 in diabetic rats. Chin Med J (Engl) 2006;119: 814-21. (Pubitemid 43796810)
30. Makino H, Miyamoto Y, Sawai K, et al. Altered gene expression related to glomerulogenesis and podocyte structure in early diabetic nephropathy of db/db mice and its restoration by pioglitazone. Diabetes 2006;55: 2747-56. (Pubitemid 44923673)
31. Guhua Z, Cai L, Lu C. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor b-independent pathway. Am J Pathol 2004;165: 2033-43. (Pubitemid 39578381)
32. Alsaad KO, Herzenberg AM. Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update. J Clin Pathol 2007;60: 18-26. (Pubitemid 46142667)
33. Koya D, Hayashi K, Kitada M, et al. Effects of antioxidants in diabetes-induced oxidative stress in the glomeruli of diabetic rats. J Am Soc Nephrol 2003;14: S250-3. (Pubitemid 36903935)
34. Prabhakar S, Starnes J, Shi S, et al. Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. J Am Soc Nephrol 2007;18: 2945-52. (Pubitemid 350058402)
35. Lin CC, Lin LT, Yen MH, et al. Renal protective effect of xiao-chai-hu-tang on diabetic nephropathy of type 1-diabetic mice. Evid Based Complement Alternat Med 2012; 2012: 984024.
36. Fararh KM, Shimizu Y, Shiina T, et al. Thymoquinone reduces hepatic glucose production in diabetic hamsters. Res Vet Sci 2005;79: 219-23. (Pubitemid 41070359)
37. El-Dakhakhny M, Madi NJ, Lembert N, Ammon HP. Nigella sativa oil, nigellone and derived thymoquinone inhibit synthesis of 5-lipoxygenase products in polymorphonuclear leukocytes from rats. J Ethnopharmacol 2002;81: 161-4. (Pubitemid 34628498)